CARIBOU COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 201 cases of invasive cancer were diagnosed among Caribou County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in CaribouCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Caribou County	State of Idaho
All Sites/Types	201	47,333
Female Breast	26	6,943
Prostate	33	6,766
Lung & Bronchus	18	4,959
Colorectal	14	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Caribou County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Caribou County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 55 Caribou County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Caribou County and the State of Idaho, 2018–2022

Mortality 2018–2022	Caribou County	State of Idaho				
All Deaths	365	80,538				
Cancer Deaths	55	15,233				
% of All Deaths	15.1%	18.9%				
Lung & Bronchus	11	2,937				
Colorectal	3	1,332				
Pancreas	2	1,190				
Female Breast	3	1,111				
Prostate	1	997				

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Caribou County was 568.1 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.2) gives an estimate of the relative burden of disease in Caribou County.

The age- and sex-adjusted incidence rate of invasive cancer in Caribou County, all sites combined, was 540.8 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Caribou County (201) than expected (195.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Caribou County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Caribou County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Caribou County, all sites combined, was 143.9 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were fewer cancer deaths in Caribou County (55) than expected (63.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN CARIBOU COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cancer Observed Person Crude A.I. Expected Puest Rest Crude All Sites Combined fola 201 35.81 668.1 540.8 105.6 0.717 47.132 8.966.725 658.4 All Sites Combined Famile 0 17.534 245.0 8.00.5 0.717 24.442.442 454.2 456.2 7.00.0 8.85 7.65.2 44.44.31 558.3 1.66.2 7.00.0 8.85 7.65.2 44.42.442 44.2 44.2 44.2 44.2 44.2 44.2 44.2 44.2 1.00.0 8.85 1.05.7 1.66.3 1.67.2 7.6.3 1.10.00 1.85.7 1.65.6 1.1 1.000 2.74 4.462.412 1.65.3 1.63.0 2.0.0 6.65.7 1.63.1 1.00.0 8.85.7 1.63.8 1.00.0 1.63.8 1.63.8 1.00.0 1.63.8 1.63.8 1.00.0 1.63.8 1.63.8 1.00.0 1.63.8 1.63.8 1.00.0 1.63.8 1.63.8<				Car	Remainder of Idaho						
Site Crombined Years Rate (1) Rate (1) Rate (1) Rate (1) All Sites Combined Male 121 17,980 673.7 644.8 105.0 0.137 241.9 849.725 552.4 All Sites Combined Female 0 17,421 462.2 430.0 0.027 21.983 4.442.12 424.2 Bidder Male 9 77.00 24.5 24.0 19 0.0285 147.442.12 402.12 Bidder Fenale 17,421 - - 19 0.0285 14.742.12 75 Binder Fenale 17,421 57 5.5 1.1 10.00 221.4 4.44.312 25 7.5 Brain and Other CNS - non-malignant Nales 1 77.23 7.4 54.4 4.3 0.028.5 7.7 7.4 7.44 4.4 0.028.5 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.4 1.6 1.6	Cancer										
All Siles Combined Nate 201 35.381 698.1 940.8 195.6 0.717 47.132 8.396.725 526. All Siles Combined Famale 60 17.721 450.8 60.2 0.337 25.148 4.442.412 642.4 All Siles Combined Famale 60 17.721 469.7 644.6 105.0 0.337 25.148 4.442.412 442.4 Bill dofer Main 8 17.650 4.445.3 35.031 50.0 53.0 53.037		Sex	0.000.000		÷ · · · · ·			P-Value (4)	-		Rate (1)
All Siles Combined Male 121 17,960 67.77 64.46 105.0 0.137 25.149 4.462.412 4242.42 Bladder Troul 6 37.200 220.8 0.030 21.88.4 4.462.412 4242.42 Bladder Fernale - 17.421 4.56.2 20.88 90.22 0.396 21.88.4 4.462.412 10.993 Brain - mailgnant Male 1 7.66.0 5.5 5.5 2.7 0.993 655 8.55 4.14 10.000 39.1 4.443.431 8.8 Brain and off-CNS - non-mailgnant Male 1 7.660 16.3 2.0 0.665 4.47 4.444.313 11. Brain and off-CNS - non-mailgnant Male 2 35.361 35.7 35.3 1.03 0.106 6.97 4.462.412 2.37 1.037 4.462.412 2.37 1.037 4.462.412 2.37 1.037 4.462.412 2.37 1.030 2.0 9.00 9.02 9.02 9.02 9.02 9.02 9.02 9.02 9.02 9.02 <		Total			()	. ,	()	. ,			526.2
All Siles Combined Fernale 80 17,421 450.2 430.9 90.2 0.306 21,983 4,462,412 422.6 20.8 9.5 0.766 22.128 4,462,412 422.6 20.8 0.5 0.766 22.128 4,462,412 42.6 20.8 0.5 0.766 22.128 4,462,412 42.6 20.8 0.5 2.7 0.398 65.5 1.74 4,462,412 62.7 1.74 4,462,412 62.7 1.75 5.5 1.1 0.000 22.7 4,462,412 62.7 63.5 1.1 0.000 22.7 4,462,412 62.7 63.6 64.7 1.60 0.022 >1.037 4,462,412 62.7 1.61 1.000 2.7 4,462,412 2.3 1.61 1.60 1.62 2.3 1.61 1.60 1.62 2.3 1.61 1.60 1.62 2.3 1.61 1.60 2.6 1.7 1.63 2.0 0.025 2.1.07 4.462,412 2.3 1.61 1.62 1.62 1.62 1.62 1.62 1.62 1.62 1.62 1.62	All Sites Combined					644.6					559.6
Bladder Male Fernate - 17,420 4.5 4.20 7.5 0.947 1,765 4.442,473 3.9 39. Bladder er analgrann Fernate - 17,427 1.0 (225 4.47 4.422,471 10.0 Brain -malignant Male - 2 07,700 5.7 5.5 1.1 1000 2.27 4.422,472 6. Frain and other CNS - non-malignamt Total 13 3.5,381 36.7 5.5 1.1 1000 2.27 4.422,472 6. Frain and other CNS - non-malignamt Male 0 17,860 16 4. 16 4. 21 3.0 0.28 39. 1.534 2.965,725 91. Brain and other CNS - non-malignamt Male 0 17,860 16 4. 16 4. 21 3.0 0.28 39. 1.534 2.965,725 91. Brain and other CNS - non-malignamt Male 0 17,860 16 4. 16 4. 21 3.0 0.00 65 4.4494,313 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	All Sites Combined		80	17,421		436.9	90.2		21,983		492.6
Bladder Famale - 17,421 - - 1.8 0.295 447 4,462,412 100 Brain - malgrant Male 1 17,860 5.7 5.5 2.1 0.999 655 9257 7.7 Brain and other CNS - non-malgrant Male 3 35,331 8.7 5.5 2.1 0.9265 4.47 4.493,312 8.7 Brain and other CNS - non-malgrant Fernale 0 17,421 7.4 4.44 3.27 0.925 1.637 4.462,412 2.23 Breast Total 2 37,860 7.5 7.1 2.83 0.705 6.962 3.947,272 7.81 Breast Total 2 37,860 7.5 5 5.5 0.176 6.962 3.956,725 1.5 1.3 0.00 4.444,313 0.0 5.7 1.60 0.00 4.444,433 0.0 0.00 4.444,433 0.0 0.00 4.444,433 0.0 0.00 1.4444,424,11	Bladder										24.7
Brain - malgrant Total 2 35,381 5.7 5.5 2.7 0.299 6655 8.965,725 7.7 0.55 2.7 0.099 6655 8.956,725 7.7 0.55 2.7 0.000 2.31 4.349,731 8.8 8.8 0.000 2.31 4.362,742 0.000 2.33 4.362,742 0.000 2.33 4.362,742 0.000 2.33 4.362,742 0.000 2.33 4.362,742 0.000 2.33 4.362,742 0.000 2.33 4.362,742 0.000 3.33 7.35 0.000 2.33 4.362,742 0.23 0.000 6.97 4.462,412 0.23 0.33 0.000 6.97 4.462,412 0.23 0.33 0.33 0.36 0.362 0.977 4.464,313 0.10 0.967 4.464,313 0.10 0.967 4.464,313 0.10 0.967 4.464,313 0.10 0.967 4.464,313 0.10 0.10 0.33 0.33 0.32 0.100 0.367 0.360			-		44.5	42.0					39.3
Brain - maigrant Male 1 17,960 5.6 5.4 1.6 1.000 381 4,494,313 8.2 Brain and other CNS - non-malgnant Tolat 13 33,381 33,741 367 353 6.3 0.025 > 1.537 8,595,723 17.1 Brain and other CNS - non-malgnant Tolat 26 35,381 73.5 71.2 28.5 0.737 6.982 8,956,723 17.1 1.000 6.6 4,494,313 1.4 Breast Tojal 26 35,381 73.5 71.2 28.5 0.737 6.6 4.494,313 1.4 Breast Tojalt 24 27.6 5.6 5.0 1.000 6.917 4.462,412 15.7 5.6 5.0 1.000 3.83 4.862,412 30.0 Breast Tojalt 14 35,381 38.6 37.7 15.0 0.829 1.9104 4.443,312 4.862,412 30.0 5.6 5.7 0.5 0.816 8						-					
Brain - malignant Fernale 1 17,421 5.7 5.5 1.1 1.000 2.74 4,482,412 6.6 Brain and other CNS - non-malignant Hale 3 17,960 16.7 16.3 2.0 0.065 4.077 4,494,313 11.1 Brain and other CNS - non-malignant Hale 3 17,960 16.7 16.3 2.0 0.055 4.077 4,494,313 11.1 Breast Insitu Total 2 33,381 5.7 5.6 5.5 0.178 1.307 6.9950,722 15.5 Breast - In situ Total 2 17,760 1.7 1.5 1.3 0.1000 1.4 4.494,313 1.0 Breast - In situ Total 2 17,721 5.7 5.5 0.1000 1.4 4.494,313 1.0 Colorectal Male 7 17,421 4.2 3.7 1.1 1.000 1.6.4 4.462,412 3.6 Colorectal Male 7								0.999			
Brain and other CNS - non-malignant Total 13 33,381 86.7 33.3 6.3 0.022 >> 1.534 6.396,722 1.734 Brain and other CNS - non-malignant Female 10 17,421 57.4 64.4 4.3 0.025 0.037 4.462,412 23.5 Breast Total 28 35.80 7.3 5.6 5.5 0.173 0.665 8.956,725 7.5 Breast Total 2 33.381 5.7 5.6 5.5 0.178 1.397 8.967,225 15.5 Breast - In situ Male - 17,960 - - 0.0 1.000 4.44,434,31 0.0 Carrix Female 7 7.760 30 3.7 6.9 1.000 1.444,431.43 4.342,441 30.0 Cabrecial Male 7 17,760 30 3.7 6.9 1.000 1.444,31.43 4.342,441 30.0 Cobrecial Male 7 17,760 <											
Brain and other CNS - non-malignant Male 3 17,960 16.7 16.3 2.0 0.665 447 4,494,313 11. Brain and other CNS - non-malignant Female 10 17,421 57.4 54.4 4.3 0.025 → 1.077 4,452.412 23. Brasat and ther CNS - non-malignant Female 2 33,381 73.5 71.2 28.5 0.731 6.982 8,950,723 78.1 Brasat in situ Female 2 17,421 149.2 144.3 2.79 0.810 6.917 4,462.412 163. Breast in situ Male - 17,960 0.0 1.000 1,361 4,452,412 163. Breast in situ Female 2 17,421 149.2 143.3 2.79 0.810 6.917 4,462.412 163. Breast in situ Female 2 17,421 11.5 11.3 5.4 0.100 1,363 4,452,412 00. Breast in situ Female 2 17,421 11.5 11.3 5.4 0.100 1,363 4,452,412 00. Breast in situ Female 2 17,421 412 37.7 8.1 0.000 1,363 4,452,412 00. Colorectal Female 7 17,461 37.7 8.9 11.000 1,363 4,452,412 03. Colorectal Female 8 17,421 442 37.5 6.9 1.000 1,364 4,462,412 03. Colorectal Female 8 17,421 442 37.5 6.9 1.000 1,364 4,462,412 03. Colorectal Female 8 17,421 442 3.75 6.9 1.000 1,364 4,462,412 03. Colorectal Female 8 17,421 45.9 44.8 5.4 0.357 1.81 0.866 1.876 4.842,412 0.36. Colorectal Female 8 17,421 45.9 5.6 5.3 0.100 4.78 4,442,312 0.1 Beaptingus Male 1 17,960 5.6 5.7 0.5 0.701 128 4,404,313 2.22 Esophagus Male 1 17,960 1.3 0.35,381 6.25 8.8 0.035 4.78 4,442,312 0.1 Beaptingus Male 1 17,960 5.6 5.7 0.5 0.701 128 4,404,313 2.2 Esophagus Male 1 17,960 1.5 6.5 7 0.5 0.701 128 4,404,313 2.2 Exophagus Male 1 17,960 1.5 6.8 5.7 0.5 0.701 128 4,404,313 2.2 Exophagus Male 1 17,960 1.5 6.5 7.0.5 0.701 128 4,404,313 2.2 Exophagus Male 1 17,960 1.1 10.7 0.7 0.303 10.404 4,422,412 4.2 Exophagus Formale Female 2 17,421 35.7 5.4 0.9 0.000 1.446 4,462,412 4.2 Exophagus Formale Female 1 17,721 3.6 7 5.4 0.2 7 0.514 6.404 4,422,412 4.2 Exophagus Formale Female 2 17,421 3.7 5.4 0.9 0.000 1.446 4,462,412 4.2 Exophagus Formale Female 1 17,960 1.1 10.7 0.7 0.303 10.664 4,462,412 4.2 Exophagus Formale Female 1 17,421 3.7 5.4 2.2 1.0 5.0 0.000 1.446 4,462,412 4.2 Exophagus Formale Female 1 17,421 3.7 5.4 2.2 1.0 1.000 5.4 4,442,313 3.3 Exophagus Formale Female 2 17,421 3.7 5.4					-						17.1
Breast Total 26 35,381 73.5 71.2 28.5 0.731 6.982 8,967,25 76.6 Breast Total 2 35,381 5.7 5.6 5.0 0.731 6.987 4.442,412 165.6 Breast Instu Total 2 35,381 5.7 5.6 5.0 0.778 6.987 4.442,412 165.6 Breast In situ Female 2 17,421 1.5 1.1 0.00 1.83 4.462,412 30.0 Colorectal Male 7 17,421 40.2 37.7 15.0 0.827 3.818 8.956,725 40.0 Colorectal Male 7 17,421 40.2 37.5 6.9 1.000 1.648 4.462,412 30.0 Colorectal Female 7 17,421 40.2 37.5 6.9 1.000 7.8 4.462,412 1.1 1.000 7.8 4.462,412 1.1 1.000 7.8	Brain and other CNS - non-malignant	Male						0.665		4,494,313	11.1
Breast Mele - 17.960 - - 0.3 0.00 66.5 4.494,313 1.1 Breast - in situ Total 2 37.331 5.7 5.6 5.5 0.178 1.300 4 4.494,313 0.0 Breast - in situ Female - 17.421 15.7 15.3 5.1 0.1000 1.284 4.462,412 15.5 Golorectal Total 4 4.3531 38.5 37.7 15.0 0.997 4.444,413 4.462,412 36.5 Colorectal Male 7 17.960 38.0 37.7 8.1 0.869 1.970 4.444,413 4.462,412 30.5 Colorectal Female 7 17.421 44.5 4.4 5.4 3.4 1.444 4.442,112 35.5 Esophagus Male 1 17.960 5.6 5.7 0.5 0.105 1.000 1.686 4.494,313 2.24 4.444,313 2.24 4.444,313	Brain and other CNS - non-malignant										23.2
Breast Female 26 17,421 149.2 143.3 27.9 0.810 6.917 4.462.412 155.1 Breast - in situ Male - 17.960 - 5 5 0.178 1.397 8.967.25 15.5 1 0.000 4.344.313 0.0 Colorectal Female 1 17.421 5.7 15.9 0.00 1.468 4.494.313 0.0 Colorectal Male 7 17.960 38.0 37.7 15.0 0.927 3.618 8.956.725 40.0 Colorectal Female 7 17.421 44.9 44.212 30.0 1.464 4.462.412 36.6 Colorectal Female 7 17.421 45.2 2.7 2.1 0.745 508 8.956.725 15.1 16.00 1.462.412 15.1 12.0 3.0 36.8 1.000 1.442.412 15.1 12.0 3.0 36.8 1.000 1.442.412 1.1 10.00			-		73.5	71.2					78.0
Breast - in situ Total 2 35,381 5.7 5.6 5.5 0.176 1,367 8,367,252 15.5 Breast - in situ Fernale 2 17,421 11.5 5.4 0.100 4,449,313 0.0 Breast - in situ Fernale 1 17,421 5.7 5.8 1.0 1.000 4,344,313 0.0 Colorectal Main 1 7.980 30.0 37.7 8.10 0.869 1.970 4,446,413 43.3 Colorectal Fernale 7 17,421 45.9 44.8 5.4 0.354 1.342 4.462,412 30.3 Colorectal Fernale - 1.7,421 - - 0.3 1.000 78 4.462,412 1.1 Sophagus Total 1 35,386 8.5 5 0.5 1.8 0.925 4.462,412 1.1 Stophagus Total 1 35,381 2.2.6 2.1 0.844,424,13 2.9					-	-					
Breast - in situ Male - 17,960 - - 0.0 1,46 4,494,313 0.0 Cervix Female 1 17,421 15.7 5.9 1.1 1.000 2,933 4,462,412 30.0 Colorectal Maine 7 7,421 15.7 5.9 1.1 1.000 2,933 4,462,412 30.0 Colorectal Maine 7 7,421 4.95 <td< td=""><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>			-								
Breast Female 2 17,421 11.5 11.3 5.4 0.190 1,363 4,462,412 30.0 Colorectal Total 14 35,381 39.6 37.7 15.0 0.927 3.618 8.956,225 40.0 Colorectal Female 7 7.7421 40.2 37.6 6.8 1.000 1.648 4.462,412 36.3 Colorectal Female 7 7.7421 40.2 37.6 6.8 1.000 1.648 4.449,413 43.3 Colorectal Female 8 7.7421 40.2 37.6 6.8 1.000 1.648 4.442,412 3.5 Esophagus Female 17.7421 7.4 - - 0.3 1.000 7.8 4.462,412 2.1 Hodgkin Lymphoma Female 17.7421 1.5 1.2 0.3 0.090 19 4.462,412 2.1 Kidney and Renal Pelvis Male 1 7.7960 38.0 3.7 <td></td> <td></td> <td>- 2</td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td>0.1</td>			- 2			-					0.1
Cervix Female 1 17,421 5.7 5.9 1.1 1.000 293 4,462,412 6.6 Colorectal Male 7 17,960 38.0 37.7 8.16 0.869 1.970 4,484,313 43. Colorectal Female 7 17,421 40.2 37.5 6.9 1.000 1.644 4,462,412 36.5 Esophagus Total 1 35.81 2.2 2.7 1.0.46 5.00 4.462,412 36.5 Esophagus Manale 1 17,960 5.6 5.7 0.5 0.50 7.8 4.462,412 2.2 Hodgkin Lymphoma Male 1 17,960 5.6 5.7 0.5 0.90 91 4.462,412 2.2 Kidney and Renal Pelvis Total 8 35,381 2.2 2.16 8.0 10.00 1.943 8.956,725 2.2 Kidney and Renal Pelvis Total 7 7.960 30.37 5.4	Breast - in situ		2		11.5	11.3			-		30.5
Colorectal Total H4 35,381 39.6 37.7 TS0 0.927 3,618 8,956,725 40.0 Colorectal Fermale 7 17,421 40.2 37,5 6.9 1,970 4,494,314 34.3 43.3 Colorectal Fermale 8 17,421 40.2 37,5 6.9 1,000 1,648 4,462,412 30.2 Esophagus Total 1 35,380 2.8 2.3 2.1 0,745 6.99 1,000 1,648 4,462,412 31.1 Hodgkin Lymphoma Fermale - 17,421 1.5 - 0.3 1,000 1,943 4,462,412 21.1 1.1 1.0 1.0 1,943 4,943,31 22.2 2.10 8.01 0.000 1,943 8,956,725 22.7 1.1 1.5 1.2 0.3 0.000 1,94 4,462,412 2.1 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4	Cervix	Female	1	17,421	5.7	5.9		1.000	293	4,462,412	6.6
Colorectal Female 7 17,421 40.2 37.5 6.9 1.000 1.648 4.462,412 39.3 Esophagus Total 1 35,381 2.8 2.7 2.1 0.746 500 8.956,725 55. Esophagus Female - 17,421 - - 0.3 1.000 78 4.462,412 1.1 Hodgkin Lymphoma Total 3 35.381 8.5 8.8 0.8 0.100 78 4.462,412 2.1 Hodgkin Lymphoma Total 1 17,960 5.6 5.7 0.3 0.000 91 4.462,412 2.1 Kitney and Renal Pelvis Fonale 7 7.421 1.5 1.2 0.3 0.000 91 4.462,412 1.4 Larynx Female 1 7.421 1.5 7 7 0.33 1.664 4.433 3.3 3.3 Larynx Female 1 17,421 5.7 2.0				35,381							40.4
Corpus Uleri Female 8 17421 44.8 5.4 0.354 1,346 4,462,412 302 Esophagus Male 1 17,960 5.6 5.3 1.8 0.925 42.8 4,494,313 9.9 Esophagus Female - 17,421 - - 0.3 1.000 7.8 4.462,412 1.1 Hodgkin Lymphoma Male 1 7,960 5.6 5.7 0.5 0.791 1.28 4,494,313 2.2 Hodgkin Lymphoma Female 2 17,421 1.5 1.2 0.0 0.90 91 4,462,412 2.1 Kidney and Renal Pelvis Male 7 17,960 30.0 37.7 5.4 0.591 1.000 1.44,494,313 22.1 Larynx Female 1 7,421 2.7 2.4 0.514 6.42,424 1.3 Larynx Female 1 7,421 2.7 2.6 2.9 0.333 6.64										4,494,313	43.8
Esophagus Total 1 35.381 2.8 2.7 2.1 0.746 506 59.3 1.8 0.925 428 4.442.412 1.1 Esophagus Female - 17.421 - - 0.3 1.000 78 4.462.412 1.1 Hodgkin Lymphoma Male 1 17.960 5.6 5.7 0.5 0.791 128 4.462.412 2.1 Hodgkin Lymphoma Female 2 7.421 1.5 1.2 0.3 0.090 91 4.462.412 2.1 Kidney and Renal Pelvis Male 1 17.960 3.5 3.7 5.4 0.591 1.000 4.491.31 3.2 Larynx Male 2 17.361 8.7 5.4 0.0 0.303 165 4.449.412 1.2 Larynx Female - 17.421 - - 0.2 1.000 5.5 1.71 1.855.75 1.92 1.000 5.6 1.031 <td>-</td> <td></td>	-										
Esophagus Male 1 17,960 5.6 5.3 1.8 0.925 428 4,494,313 9.9 Hodgin Lymphoma Total 3 35,381 8.5 8.8 0.0 0.791 128 4,494,313 2.2 Hodgin Lymphoma Female 2 17,421 1.5 12.2 0.791 128 4,494,313 2.2 Kidney and Renal Pelvis Total 8 35,381 2.7 1.5 1.000 1.943 8.956,725 2.1 Kidney and Renal Pelvis Male 7 17,960 32.0 3.7.7 5.4 0.5 0.514 404 4.462,412 4.4 Larynx Male 7 17,960 32.0 3.7.7 5.4 0.7 0.000 63 4.494,313 22.1 2.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 4.494,313 22.1 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4											
Esophagus Female - 17,421 - - 0.31 1.000 78 4,462,412 1.1 Hodgkin Lymphoma Male 1 17,960 5.6 5.7 5.0 0.791 128 4,494,313 22.4 Hodgkin Lymphoma Female 2 17,421 11.5 12.2 0.3 0.090 91 4,462,412 22.4 Kidney and Renal Pelvis Male 7 7.7,960 39.0 37.7 5.4 0.9 0.460 218 8,956,725 22.1 Larynx Total 2 35,381 5.7 5.4 0.9 0.460 218 8,956,725 22.1 Larynx Total 2 35,381 5.7 5.4 0.9 0.460 218 8,956,725 22.1 12.1 14.494,313 22.1 Larynx 14.64,44,313 22.1 14.34,443,31 22.1 Larynx 16.1 14.33,331 24.2 15.0 13.4 14.494,313 22.1 Lar											9.5
Hodgkin Lymphoma Total 3 35,381 8.5 8.8 0.105 219 8,986,725 22. Hodgkin Lymphoma Female 2 17,421 11.5 12.2 0.300 91 1,462,412 21.6 Kidney and Renal Pelvis Total 8 35,381 22.6 21.6 8.0 1.000 1943 8,956,725 22.1 Kidney and Renal Pelvis Male 7 17,960 39.0 37.7 5.4 0.591 1.303 4,462,412 1.4 Larynx Total 2 35,381 5.7 5.4 0.7 0.540 2448,4313 29.1 Larynx Female - 17,421 - - 0.2 1.000 53 4,462,412 1.5 Leukemia Total 10 35,381 28.5 7.2 1.000 582 4,462,412 15.5 Leukemia Female 17,421 2.7 5.4 1.0 1.000 246 4,462,412 <td>Esophagus</td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>4,462,412</td> <td>1.7</td>	Esophagus					-				4,462,412	1.7
Hodginu Lýmphoma Fernale 2 17.421 11.5 12.2 0.3 0.090 91 4.462.412 22. Kidney and Renal Pelvis Male 7 17.960 39.0 37.7 5.4 0.591 1.303 4.494.313 22.0 Kidney and Renal Pelvis Fernale 1 17.421 5.7 5.4 2.7 0.514 640 4.462.412 1.4 Larynx Total 2 35.381 5.7 5.4 0.9 0.460 218 8.556.725 2.2 Larynx Fernale - 17.421 - - 0.2 1.000 53 4.462.412 1.7 Leukemia Total 3 35.381 28.5 7.2 0.385 1.011 4.494.313 22.5 1.000 53 4.462.412 15.7 Leukemia Fernale 17.960 27.8 26.6 2.9 0.333 68.6 4.462.412 15.5 Liver and Bile Duct Total <td< td=""><td>Hodgkin Lymphoma</td><td></td><td>3</td><td>35,381</td><td>8.5</td><td>8.8</td><td>0.8</td><td>0.105</td><td>219</td><td></td><td>2.4</td></td<>	Hodgkin Lymphoma		3	35,381	8.5	8.8	0.8	0.105	219		2.4
Kindrey and Renal Pelvis Total 8 35,381 22.6 21.6 8.0 1.000 1,943 8,956,725 21.1 Kidney and Renal Pelvis Female 1 17,421 5.7 5.4 0.514 640 4,462,412 14.3 Larynx Iotal 2 35,381 5.7 5.4 0.9 0.460 218 8,956,725 22.2 Larynx Male 2 35,381 5.7 5.4 0.9 0.460 218 8,956,725 12.1 Larynx Female - 17,421 - - 0.033 166 4,494,313 32.2 Leukemia Male 5 17,960 27.8 26.6 4.3 0.865 1.031 4,494,313 132.2 Liver and Bile Duct Total 3 35.381 8.5 8.1 3.5 1000 840 4,896,725 59.9 Liver and Bile Duct Total 1.742 5.7 5.4 1.0 1.000	Hodgkin Lymphoma										2.8
Kidney and Renal Pelvis Male 7 17,960 39.0 37.7 5.4 0.591 1,303 4,494,313 29.0 Larynx Tolal 2 35,381 5.7 5.4 0.7 0.514 640 218 8,956,725 22. Larynx Female - 17,421 - - 0.2 1000 53 4,462,412 13.3 Larynx Female - 17,421 - - 0.2 1000 53 4,462,412 13.3 Laukemia Total 10 35,381 28.5 7.2 0.385 1,017 8,956,725 193.0 Leukemia Female 1 17,421 5.7 5.4 1.0 1000 544 4,462,412 15.7 Liver and Bile Duct Male 2 17,960 61.1 10.6 2.5 1000 840 8,96,725 55.7 Lung and Bronchus Total 18 35,381 8.5.4 4.40											2.0
Kidney and Renal Pelvis Female 1 17,421 5.7 5.4 2.7 0.514 640 64,462,412 14.5 Larynx Male 2 17,960 11.1 10.7 0.7 0.303 165 4,494,413 3.3 Larynx Female - - - 0.2 10.00 53 4,462,412 1.1 Leukemia Total 35,381 28.3 28.5 7.2 0.385 1,717 8.956,725 2.9 Leukemia Total 35,381 28.3 28.5 7.2 0.385 1,717 8.956,725 9.2 Liver and Bile Duct Total 3 33.81 8.5 8.1 3.5 10.00 840 8.956,725 9.2 Liver and Bile Duct Male 1 17,421 5.7 5.4 1.0 1.000 24.849,4313 15.5 Lung and Bronchus Mele 12 17,960 66.8 66.30 10.5 0.257 1.858											
Larynx Total 2 35.381 5.7 5.4 0.9 0.460 218 8.956,725 2.2 Larynx Female - 17.421 - - 0.2 1.000 53 4.462.412 1.1 Leukemia Total 10 35.381 28.3 26.5 7.2 0.385 1.717 8.956,725 1.92 Leukemia Male 5 17.460 27.8 26.6 4.3 0.865 1.031 4.494.413 32.2 Liver and Bile Duct Total 3 35.381 8.5 8.1 3.5 1.000 840 8.956,725 1.92 Liver and Bile Duct Total 1 7.460 1.1 1.06 2.5 1.000 24.44 4.462.412 5.5 Lung and Bronchus Total 18 35.381 50.9 4.72 21.0 0.597 4.941 8.966,725 55.5 Lung and Bronchus Female 17.421 34.452 31.5											
Larjnx Male 2 17,960 11.1 10.7 0.7 0.303 165 4,494,313 33. Larynx Female - 17,421 - - 0.2 1.000 53 44,62,412 1.1 Leukemia Male 5 17,960 27.8 26.6 2.9 0.333 686 4462,412 1.5 Leukemia Female 5 17,421 28.7 26.6 2.9 0.333 686 4462,412 1.5 Liver and Bile Duct Male 2 17,960 1.1 10.6 2.5 1.000 28.4 4,462,412 5.6 Lurg and Bronchus Total 18 3.35.81 50.9 47.2 21.0 0.597 4.344 3.5 55.7 1.05 0.257 2.488 4.494,313 55.7 1.05 0.257 3.48 4.494,313 55.7 53.5 1.05 0.252 2.488 4.462,412 55.7 Melanom of the Skin											2.4
Larýnx Female - 17,421 - - 0.2 1.000 53 4,462,412 1.1 Leukemia Male 5 17,960 27,8 26,6 4,3 0,865 1,717 8,956,725 193 Leukemia Female 5 17,421 28,7 26,6 4,3 0,865 1,031 4,494,313 22,2 Lever and Bile Duct Total 3 35,381 8,5 8,1 3,5 1,000 840 8,956,725 9,4 Liver and Bile Duct Female 1 1,7421 5,7 5,4 1,0 1,000 248 4,462,412 5,5 Lung and Bronchus Male 12 1,7960 66,8 63,0 10,5 0,205 2,483 4,494,313 55,5 Lung and Bronchus Female 17,421 3,4 33,5 5,0 0,766 1,243 4,462,412 55,7 Melanoma of the Skin Male 10 17,960 27,8 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>3.7</td></td<>											3.7
Leukemia Male 5 17,960 27,8 26,6 4.3 0.865 1.031 4,494,313 222. Liver and Bile Duct Total 3 35,381 8.5 8.1 35 1000 840 8,956,725 99 Liver and Bile Duct Female 1 17,421 25,7 5,4 1.000 248 4,462,412 5,1 Lung and Bronchus Total 18 35,381 50.9 47,2 21.0 0.597 4,941 8,956,725 55.5 Lung and Bronchus Female 6 17,421 3,44 31.5 10.5 0.205 2,483 4,494,313 55.5 Lung and Bronchus Female 6 17,421 34.4 31.5 10.5 0.205 2,483 4,494,313 41.9 Melanoma of the Skin Male 10 17,960 65.7 53.5 7.8 0.527 1.885 4,494,313 41.9 Myeloma Total 7 35.381 1		Female		17,421	-	-	0.2	1.000		4,462,412	1.2
Leukemia Female 5 17,421 28.7 26.6 2.9 0.333 666 4,462,412 15.5 Liver and Bile Duct Male 2 35,381 8.5 8.1 3.5 1.000 592 4,492,412 15.7 Liver and Bile Duct Female 1 17,421 5.7 5.4 1.0 1.000 224 4,462,412 5.6 Lung and Bronchus Male 12 17,960 66.8 63.0 10.5 0.728 2,483 4,494,313 55.5 Lung and Bronchus Male 10 17,960 65.7 55.5 7.8 0.527 1.885 4,494,313 451.5 Melanoma of the Skin Total 16 35.381 452.4 43.4 12.9 0.452 3.128 8.956,725 34.3 Melanoma of the Skin Female 6 17,421 34.4 33.5 5.0 0.766 1,243 4,462,412 27.7 Myeloma Total 7 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>19.2</td></td<>											19.2
Liver and Bile Duct Total 3 35,381 8.5 8.1 3.5 1.000 840 8956,725 9.9. Liver and Bile Duct Fernale 2 17,960 11.1 10.6 2.5 1.000 592 4,494,313 13.2. Liver and Bile Duct Fernale 1 17,421 5.7 5.4 1.0 0.0 248 4,462,412 5.6. Lung and Bronchus Total 18 35,381 50.9 47.2 21.0 0.597 4,941 8,956,725 55.5. Lung and Bronchus Male 12 17,960 66.8 63.0 10.5 0.728 2,483 4,494,313 55.5. Lung and Bronchus Fernale 6 17,421 34.4 31.5 10.5 0.205 2,458 4,462,412 55. Melanoma of the Skin Total 16 35,381 45.2 43.4 12.9 0.452 3,128 8,956,725 33.4 Melanoma of the Skin Total 16 35,381 45.2 43.4 12.9 0.452 3,128 8,956,725 34.4 Melanoma of the Skin Total 16 35,381 45.2 43.4 12.9 0.452 3,128 8,956,725 34.4 Melanoma of the Skin Total 16 37,836 19.8 18.5 3.0 0.071 721 8,956,725 48. Melanoma of the Skin Fernale 6 17,421 34.4 33.5 5.0 0.766 1,243 4,462,412 27.5 Myeloma Male 5 17,960 27.8 26.5 1.9 0.081 442 4,494,313 9.8 Myeloma Male 5 17,960 27.8 26.5 1.9 0.081 4422 4,494,313 9.8 Myeloma Male 6 17,960 33.4 32.1 4.7 0.679 1,140 4,494,313 25.5 Oral Cavity and Pharynx Total 6 35,381 17.0 16.3 5.4 0.902 1,309 8,956,725 22.22 Non-Hodgkin Lymphoma Fernale 3 17,421 17.2 16.1 3.5 1.000 843 4,462,412 65. Oral Cavity and Pharynx Male 4 17,960 22.3 21.4 3.9 1.000 936 4,494,313 20.5 Oral Cavity and Pharynx Male 3 17,960 16.7 15.9 0.51 1,300 843 4,462,412 18.9 Oral Cavity and Pharynx Male 3 17,960 16.7 15.9 0.51 1,000 823 4,494,313 20.5 Oral Cavity and Pharynx Male 3 17,960 16.7 15.9 0.51 0.910 373 4,462,412 18.9 Pancreas Fernale 2 17,421 2 0.214 553 4,462,412 18.9 Oral Cavity and Pharynx Male 3 17,960 16.7 15.9 0.52 6.1 1,300 823 4,494,313 18.7 Pancreas Fernale - 17,421 0.7 0.988 167 614 4,462,412 18.9 Stomach Male 1 17,960 5.6 5.3 1.3 1.000 823 4,494,313 18.7 Pancreas Fernale - 17,421 0.7 0.988 167 614 4,462,412 18.9 Stomach Fernale - 17,421 0.7 0.988 167 614 4,462,412 18.9 Stomach Fernale - 17,421 0.7 0.988 167 613 4,462,412 18.9 Stomach Fernale - 17,421 0.7 0.988 167 613 4,462,412 18.9 Pancreas Fernale											
Liver and Bile Duct Female 1 17,960 11.1 10.6 2.5 1.000 592 4.494,313 13.3 13.3 13.3 13.3 13.3 13.3 13.3											
Liver and Bile Duct Female 1 17.421 5.7 5.4 1.00 248 4.462.412 5.1 Lung and Bronchus Male 12 17.960 66.8 63.0 10.5 0.728 2.483 4.494.313 55.5 Lung and Bronchus Female 6 17.421 34.4 31.5 10.5 0.728 2.483 4.494.313 55.5 Melanoma of the Skin Total 16 35.381 45.2 43.4 12.9 0.452 3.128 8.956.725 34.3 Melanoma of the Skin Male 10 17.960 55.7 53.5 0.78 0.527 1.885 4.494.313 9.1 Myeloma Total 7 35.381 19.8 18.5 3.0 0.071 721 8.956.725 8.8 Non-Hodgkin Lymphoma Temale 2 17.421 11.5 10.7 1.2 0.654 2.79 4.462.412 6.8 Non-Hodgkin Lymphoma Total 9 35.381<											
Lung and Bronchus Total 18 35,381 50.9 47.2 21.0 0.597 4.941 8.956,725 55.5 Lung and Bronchus Female 6 17,421 34.4 31.5 10.5 0.728 2,483 4,494,313 55.7 Lung and Bronchus Female 6 17,421 34.4 31.5 10.5 0.205 2,488 4,494,313 41.9 Melanoma of the Skin Male 10 17,960 55.7 53.5 7.8 0.527 1,885 4,94,313 41.9 Melanoma of the Skin Female 6 17,421 34.4 33.5 5.0 0.766 1,243 4,462,412 27.7 Myeloma Male 5 17,960 27.8 26.5 1.9 0.081 424 4,494,313 25.4 Myeloma Female 2 17,421 11.5 10.7 1.2 0.654 279 4,462,412 63.7 Non-Hodgkin Lymphoma Total 6 17,960 33.4 32.1 4.7 0.679 1,140 4,494,313 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>4.462.412</td><td>5.6</td></td<>										4.462.412	5.6
Lung and Bronchus Male 12 17,960 66.8 63.0 10.5 0.728 2,483 4,494,313 55.7 Lung and Bronchus Female 6 17,421 34.4 31.5 10.5 0.205 2,458 4,462,412 55.7 Melanoma of the Skin Male 10 17,960 55.7 53.5 7.8 0.527 1,885 4,494,313 44.52 Melanoma of the Skin Female 6 17,421 34.4 33.5 5.0 0.766 1,243 4,462,412 27.7 Myeloma Male 5 17,960 27.8 26.5 1.9 0.081 44.2 4,494,313 9.8 Myeloma Male 6 17,421 11.5 10.7 1.2 0.654 279 4,462,412 63. Non-Hodgkin Lymphoma Male 6 17,960 32.4 32.1 4.7 0.679 1,140 4,494,313 25.4 Non-Hodgkin Lymphoma Female 17,421											55.2
Melanoma of the Skin Total 16 35.381 45.2 43.4 12.9 0.452 3.128 8.956.725 34.9 Melanoma of the Skin Female 6 17,421 34.4 33.5 50 0.527 1,885 4,494,313 41.3 Myeloma Total 7 35,381 19.8 18.5 3.0 0.071 721 8,956,725 80.5 Myeloma Male 5 17,421 34.4 33.5 50 0.076 1,243 4,462,412 27.5 80.5 Myeloma Male 5 17,960 27.8 26.5 1.9 0.081 442 4,494,313 99.5 Non-Hodgkin Lymphoma Male 6 17,960 33.4 32.1 4.7 0.679 1,140 4,494,313 99.5 22.5 22.5 Non-Hodgkin Lymphoma Male 6 17,920 33.4 32.1 4.7 0.679 1,140 4,494,313 99.5 22.5 22.5 Non-Hodgkin Lymphoma Female 3 17,421 17.2 16.1 <	Lung and Bronchus				66.8		10.5	0.728		4,494,313	55.2
Melanoma of the Skin Male 10 17,960 55.7 53.5 7.8 0.527 1,885 4,494,313 41.5 Melanoma of the Skin Female 6 17,421 34.4 33.5 5.0 0.766 1,243 4,462,412 27.8 Myeloma Male 5 17,960 27.8 26.5 1.9 0.081 442 4,494,313 9.8 Myeloma Female 2 17,421 11.5 10.7 1.2 0.654 279 4,462,412 6.2 Non-Hodgkin Lymphoma Total 9 35,31 25.4 24.2 8.2 0.882 1.983 8956.725 14.0 Non-Hodgkin Lymphoma Female 3 17,421 17.2 16.1 3.5 1.000 843 4,462,412 82.0 1.988 956.725 14.0 0ral Cavity and Pharynx Total 6 35,381 17.0 16.3 5.4 0.902 1.308 8,956.725 14.0 0ral Cavity and Pharynx											55.1
Melanoma of the Skin Female 6 17,421 34.4 33.5 5.0 0.766 1,243 4,462,412 27.5 Myeloma Male 5 17,960 27.8 26.5 1.9 0.081 442 4,494,313 9.8 Myeloma Female 2 17,421 11.5 10.7 1.2 0.654 27.9 4,462,412 6.3 Mon-Hodgkin Lymphoma Female 2 17,421 11.5 10.7 1.2 0.654 27.9 4,462,412 6.3 Non-Hodgkin Lymphoma Male 6 17,960 3.4 32.1 4.7 0.679 1,140 4,494,313 25.4 Non-Hodgkin Lymphoma Female 3 17,421 17.2 16.1 3.5 1.000 843 4,462,412 18.9 Oral Cavity and Pharynx Total 6 35,381 17.0 16.3 5.4 0.902 1,309 8,956,725 14.0 Oral Cavity and Pharynx Male 17,421 <td></td> <td>34.9</td>											34.9
Myeloma Total 7 35,381 19.8 18.5 3.0 0.071 721 8,956,725 8.0 Myeloma Female 2 17,421 11.5 10.7 12 0.654 279 4,462,412 6.5 Non-Hodgkin Lymphoma Total 9 35,381 25.4 24.2 8.2 0.882 1,983 8,956,725 22.7 Non-Hodgkin Lymphoma Male 6 17,960 33.4 32.1 4.7 0.679 1,140 4,494,313 25.4 Non-Hodgkin Lymphoma Female 3 17,421 17.2 16.1 3.5 1.000 843 4,462,412 18.5 Oral Cavity and Pharynx Total 6 35,381 17.0 16.3 5.4 0.902 1,309 8,956,725 14.6 Oral Cavity and Pharynx Male 4 17,960 22.3 21.4 3.9 1.000 936 4,494,313 20.6 Ovary Female 17,421 -<											
Myeloma Male 5 17,960 27.8 26.5 1.9 0.081 442 4,494,313 94 Myeloma Female 2 17,421 11.5 10.7 1.2 0.081 442 4,494,313 94 Mon-Hodgkin Lymphoma Total 9 35,381 25.4 24.2 8.2 0.882 1,983 8,956,725 22.2 Non-Hodgkin Lymphoma Female 3 17,421 17.2 16.1 3.5 1.000 843 4,462,412 183 Oral Cavity and Pharynx Total 6 35,381 17.0 16.3 5.4 0.902 1,309 8,956,725 14.0 Oral Cavity and Pharynx Total 6 35,381 17.0 16.3 5.4 0.902 1,309 8,956,725 14.0 Oral Cavity and Pharynx Female 2 17,421 11.5 10.9 1.5 0.910 373 4,462,412 8.0 Ovary Female 17,421			-								27.9
MýelomaFemale217,42111.510.71.20.6542794,462,4126.3Non-Hodgkin LymphomaTotal935,38125.424.28.20.8821,9838,956,72522.3Non-Hodgkin LymphomaFemale317,42117.216.13.51.0008434,462,41218.3Oral Cavity and PharynxTotal635,38117.016.35.40.9021,3098,956,72514.6Oral Cavity and PharynxMale417,96022.321.43.91.0003364,494,31320.8Oral Cavity and PharynxFemale217,4212.20.2145534,462,4128.2OvaryFemale-17,4212.20.2145534,462,41214.8PancreasTotal435,38111.310.56.30.4971,484895,72516.6PancreasMale317,96016.715.93.51.0008234,494,31318.5PancreasMale117,9605.65.31.31.0003064,494,31314.9StomachMale117,9605.65.31.31.0003064,494,3136.5StomachMale117,9605.65.31.31.0003064,494,3136.5StomachMale117,96016.7 <td< td=""><td></td><td></td><td>_</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>9.8</td></td<>			_								9.8
Non-Hodgkin Lymphoma Total 9 35,381 25.4 24.2 8.2 0.882 1,983 8,956,725 22.7 Non-Hodgkin Lymphoma Female 3 17,421 17.2 16.1 3.5 1.000 843 4,494,313 25.4 Non-Hodgkin Lymphoma Female 3 17,421 17.2 16.1 3.5 1.000 843 4,494,313 25.4 Oral Cavity and Pharynx Total 6 35,381 17.0 16.3 5.4 0.902 1,309 8,956,725 14.4 Oral Cavity and Pharynx Male 4 17,960 22.3 21.4 3.9 1.000 936 4,494,313 20.6 Oral Cavity and Pharynx Female 2 17,421 - - 22.0 0.214 553 4,462,412 18.5 Ovary Female 3 17,960 16.7 15.9 3.5 1.000 823 4,494,313 18.5 Pancreas Male 3	Myeloma					10.7					6.3
Non-Hodgkin Lymphoma Male 6 17,960 33.4 32.1 4.7 0.679 1,140 4,494,313 25.4 Non-Hodgkin Lymphoma Female 3 17,421 17.2 16.1 3.5 1.000 843 4,462,412 18.9 Oral Cavity and Pharynx Male 6 35,381 17.0 16.3 5.4 0.902 1,309 8,956,725 14.0 Oral Cavity and Pharynx Male 4 17,960 22.3 21.4 3.9 1.000 93.6 4,494,313 20.8 Oral Cavity and Pharynx Female 2 17,421 11.5 10.9 1.5 0.910 373 4,462,412 8.9 Ovary Female - 17,421 - - 2.2 0.214 553 4,462,412 12.9 Pancreas Male 3 17,960 16.7 15.9 3.5 1.000 823 4,494,313 149.9 Prostate Male 3 17,960 <td>Non-Hodgkin Lymphoma</td> <td>Total</td> <td>9</td> <td>35,381</td> <td>25.4</td> <td>24.2</td> <td>8.2</td> <td>0.882</td> <td></td> <td>8,956,725</td> <td>22.1</td>	Non-Hodgkin Lymphoma	Total	9	35,381	25.4	24.2	8.2	0.882		8,956,725	22.1
Oral Cavity and Pharynx Total 6 35,381 17.0 16.3 5.4 0.902 1,309 8,956,725 14.6 Oral Cavity and Pharynx Male 4 17,960 22.3 21.4 3.9 1.000 936 4,494,313 20.8 Oral Cavity and Pharynx Female 2 17,421 11.5 10.9 1.5 0.910 373 4,462,412 8.4 Ovary Female - 17,421 - - 2.2 0.214 553 4,462,412 8.4 Pancreas Total 4 35,381 11.3 10.5 6.3 0.497 1,484 8,956,725 16.6 Pancreas Male 3 17,960 16.7 15.9 3.5 1.000 823 4,494,313 18.5 Pancreas Male 3 17,960 183.7 174.9 28.3 0.419 6,733 4,494,313 149.5 Stomach Male 1 17,960 183.7 </td <td>Non-Hodgkin Lymphoma</td> <td></td> <td></td> <td></td> <td></td> <td>32.1</td> <td></td> <td></td> <td></td> <td></td> <td>25.4</td>	Non-Hodgkin Lymphoma					32.1					25.4
Oral Cavitý and Pharýnx Male 4 17,960 22.3 21.4 3.9 1.000 936 4,494,313 20.8 Oral Cavity and Pharynx Female 2 17,421 11.5 10.9 1.5 0.910 373 4,462,412 84 Ovary Female - 17,421 - - 2.2 0.214 553 4,462,412 84 Pancreas Total 4 35,381 11.3 10.5 6.3 0.497 1,484 8,956,725 166 Pancreas Male 3 17,960 16.7 15.9 3.5 1.000 823 4,494,313 183 Pancreas Female 1 17,421 5.7 5.3 2.8 0.457 661 4,462,412 148 Prostate Male 3 17,960 183.7 174.9 28.3 0.419 6,733 4,494,313 149.8 Stomach Male 1 17,960 16.8 1.3											18.9
Oral Cavity and Pharynx Female 2 17,421 11.5 10.9 1.5 0.910 373 4,462,412 8.4 Ovary Female - 17,421 - - 2.2 0.214 553 4,462,412 12.4 Pancreas Total 4 35,381 11.3 10.5 6.3 0.497 1,484 8,956,725 16.6 Pancreas Male 3 17,960 16.7 15.9 3.5 1.000 823 4,494,313 18.5 Pancreas Male 3 17,960 183.7 174.9 28.3 0.419 6,733 4,494,313 149.6 Prostate Male 1 17,960 183.7 174.9 28.3 0.419 6,733 4,494,313 149.6 Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Male 1 17,960 5.6 5.3											14.6
Ovary Female - 17,421 - - 2.2 0.214 553 4,462,412 12.4 Pancreas Total 4 35,381 11.3 10.5 6.3 0.497 1,484 8,956,725 16.6 Pancreas Male 3 17,960 16.7 15.9 3.5 1.000 823 4,494,313 18.5 Pancreas Female 1 17,421 5.7 5.3 2.8 0.457 66.1 4,462,412 14.8 Prostate Male 33 17,960 183.7 174.9 28.3 0.419 6,733 4,494,313 149.8 Stomach Total 1 35,381 2.8 2.7 2.0 0.821 473 8,956,725 5.5 5.5 Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Male 2 17,960 11.1 12.2											
Pancreas Total 4 35,381 11.3 10.5 6.3 0.497 1,484 8,956,725 16.6 Pancreas Male 3 17,960 16.7 15.9 3.5 1.000 823 4,494,313 18.5 Pancreas Female 1 17,421 5.7 5.3 2.8 0.457 661 4,462,412 14.8 Prostate Male 33 17,960 183.7 174.9 28.3 0.419 6,733 4,494,313 149.8 Stomach Total 1 35,381 2.8 2.7 2.0 0.821 473 8,956,725 5.5. Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Male 2 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Female - 17,421 - - 0.7											12.4
Pancreas Male 3 17,960 16.7 15.9 3.5 1.000 823 4,494,313 18.5 Pancreas Female 1 17,421 5.7 5.3 2.8 0.457 661 4,462,412 14.8 Prostate Male 33 17,960 183.7 174.9 28.3 0.419 6,733 4,494,313 149.8 Stomach Total 1 35,381 2.8 2.7 2.0 0.821 473 8,956,725 5.5 Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Female - 17,421 - - 0.7 0.988 167 4,462,412 3.7 Thyroid Total 3 35,381 8.5 8.7 4.6 0.6	Pancreas										16.6
Pancreas Female 1 17,421 5.7 5.3 2.8 0.457 661 4,462,412 14.8 Prostate Male 33 17,960 183.7 174.9 28.3 0.419 6,733 4,494,313 149.8 Stomach Total 1 35,381 2.8 2.7 2.0 0.821 473 8,956,725 5.5 Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Female - 17,421 - - 0.7 0.988 167 4,462,412 3.3 Testis Male 2 17,960 11.1 12.2 1.0 0.526 272 4,494,313 6.7 Thyroid Total 3 35,381 8.5 8.7 4.6 0.665<	Pancreas										18.3
Stomach Total 1 35,381 2.8 2.7 2.0 0.821 473 8,956,725 5.7 Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Female - 17,421 - - 0.7 0.988 167 4,462,412 3.7 Testis Male 2 17,960 11.1 12.2 1.0 0.526 272 4,494,313 6.7 Thyroid Total 3 35,381 8.5 8.7 4.6 0.665 1,182 8,956,725 13.7 Thyroid Total 3 35,381 8.5 8.7 4.6 0.665 1,182 8,956,725 13.7 Thyroid Male 3 17,960 16.7 16.6 1.5 0.375 369 4,494,313 8.7 Thyroid Female - 17,421 - - 3.0 0.096				17,421	5.7	5.3	2.8		661	4,462,412	14.8
Stomach Male 1 17,960 5.6 5.3 1.3 1.000 306 4,494,313 6.8 Stomach Female - 17,421 - - 0.7 0.988 167 4,462,412 3.7 Testis Male 2 17,421 - - 0.7 0.988 167 4,462,412 3.7 Testis Male 2 17,960 11.1 12.2 1.0 0.526 272 4,494,313 6.7 Thyroid Total 3 35,381 8.5 8.7 4.6 0.665 1,182 8,956,725 13.7 Thyroid Male 3 17,960 16.7 16.6 1.5 0.375 369 4,494,313 8.7 Thyroid Female - 17,421 - - 3.0 0.096 813 4,462,412 18.7 Pediatric Age 0 to 19 Total 1 10,941 9.1 9.2 1.8 0.898 <td>Prostate</td> <td></td> <td>33</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>149.8</td>	Prostate		33								149.8
Stomach Female - 17,421 - - 0.7 0.988 167 4,462,412 3.1 Testis Male 2 17,960 11.1 12.2 1.0 0.526 272 4,494,313 6.7 Thyroid Total 3 35,381 8.5 8.7 4.6 0.665 1,182 8,956,725 13.2 Thyroid Male 3 17,960 16.7 16.6 1.5 0.375 369 4,494,313 8.2 Thyroid Male 3 17,960 16.7 16.6 1.5 0.375 369 4,494,313 8.2 Thyroid Female - 17,421 - - 3.0 0.096 813 4,462,412 18.2 Pediatric Age 0 to 19 Total 1 10,941 9.1 9.2 1.8 0.898 424 2,488,383 17.0 Pediatric Age 0 to 19 Male - 5,621 - - 0.9			1								5.3
TestisMale217,96011.112.21.00.5262724,494,3136.7ThyroidTotal335,3818.58.74.60.6651,1828,956,72513.2ThyroidMale317,96016.716.61.50.3753694,494,3138.2ThyroidFemale-17,4213.00.0968134,462,41218.2Pediatric Age 0 to 19Total110,9419.19.21.80.8984242,488,38317.0Pediatric Age 0 to 19Male-5,6210.90.7772141,268,70016.5			1		5.6	5.3					6.8 3.7
Thyroid Total 3 35,381 8.5 8.7 4.6 0.665 1,182 8,956,725 13.2 Thyroid Male 3 17,960 16.7 16.6 1.5 0.375 369 4,494,313 8.2 Thyroid Female - 17,421 - - 3.0 0.096 813 4,462,412 18.2 Pediatric Age 0 to 19 Total 1 10,941 9.1 9.2 1.8 0.898 424 2,488,383 17.0 Pediatric Age 0 to 19 Male - 5,621 - - 0.9 0.777 214 1,268,700 16.9			-		- 11 1	- 12.2				4,402,412	6.1
Thyroid Male 3 17,960 16.7 16.6 1.5 0.375 369 4,494,313 8.2 Thyroid Female - 17,421 - - 3.0 0.096 813 4,462,412 18.2 Pediatric Age 0 to 19 Total 1 10,941 9.1 9.2 1.8 0.898 424 2,488,383 17.0 Pediatric Age 0 to 19 Male - 5,621 - - 0.9 0.777 214 1,268,700 16.5											
Thyroid Female - 17,421 - - 3.0 0.096 813 4,462,412 18.2 Pediatric Age 0 to 19 Total 1 10,941 9.1 9.2 1.8 0.898 424 2,488,383 17.0 Pediatric Age 0 to 19 Male - 5,621 - - 0.9 0.777 214 1,268,700 16.9											8.2
Pediatric Age 0 to 19 Total 1 10,941 9.1 9.2 1.8 0.898 424 2,488,383 17.0 Pediatric Age 0 to 19 Male - 5,621 - - 0.9 0.777 214 1,268,700 16.9					-	-					18.2
Pediatric Age 0 to 19 Male - 5,621 0.9 0.777 214 1,268,700 16.9						92					17.0
			- '	,	-	-					16.9
	Pediatric Age 0 to 19	Female	1	5,320	18.8	19.2	0.9	1.000	210	1,219,683	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN CARIBOU COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Car	Remainder of Idaho							
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed Person Crude			
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)	
All Causes of Death	Total	365	35,591	1,025.5	939.5	339.4	0.176	80,170	9,175,803	873.7	
All Causes of Death	Male	184	18,057	1,025.5	939.5 975.5	174.3	0.170	42,602	4,609,640	924.2	
All Causes of Death	Female	181	17,534	1,019.0	902.7	165.0	0.483	37,568	4,566,163	822.7	
All Malignant Cancers	Total	55	35,591	154.5	143.9	63.2	0.332	15,178	9,175,803	165.4	
All Malignant Cancers	Male	31	18,057	171.7	163.7	33.7	0.723	8,204	4,609,640	178.0	
All Malignant Cancers	Female	24	17,534	136.9	125.2	29.3	0.381	6,974	4,566,163	152.7	
Bladder	Total	2	35,591	5.6	5.1	2.1	1.000	483	9,175,803	5.3	
Bladder	Male	2	18,057	11.1	10.4	1.6	0.918	373	4,609,640	8.1	
Bladder	Female	-	17,534	-	-	0.5	1.000	110	4,566,163	2.4	
Brain and Other Nervous System	Total	1	35,591	2.8	2.7	2.1	0.771	517	9,175,803	5.6	
Brain and Other Nervous System	Male	-	18,057	-	-	1.2	0.625	289	4,609,640	6.3	
Brain and Other Nervous System	Female	1	17,534	5.7	5.5	0.9	1.000	228	4,566,163	5.0	
Breast	Total	3	35,591	8.4	7.9	4.6	0.638	1,121	9,175,803	12.2	
Breast	Male		18,057	-	-	0.1	1.000	13	4,609,640	0.3	
Breast Cervix	Female Female	- 3	17,534 17,534	17.1	15.8	4.6 0.3	0.649	1,108 88	4,566,163 4,566,163	24.3 1.9	
Colorectal	Total	- 3	35,591	- 8.4	- 7.9	0.3	0.407	1,329	4,566,163	1.9	
Colorectal	Male	5 1	18,057	5.5	5.3	3.0	0.407	731	4,609,640	14.5	
Colorectal	Female	2	17,534	11.4	10.4	2.5	1.000	598	4,566,163	13.1	
Corpus Uteri	Female	1	17,534	5.7	5.4	0.7	0.993	168	4,566,163	3.7	
Esophagus	Total	3	35,591	8.4	8.0	1.9	0.581	458	9,175,803	5.0	
Esophagus	Male	3	18,057	16.6	15.9	1.6	0.426	388	4,609,640	8.4	
Esophagus	Female	-	17,534	-	-	0.3	1.000	70	4,566,163	1.5	
Hodgkin Lymphoma	Total	-	35,591	-	-	0.1	1.000	25	9,175,803	0.3	
Hodgkin Lymphoma	Male	-	18,057	-	-	0.1	1.000	14	4,609,640	0.3	
Hodgkin Lymphoma	Female	-	17,534	-	-	0.0	1.000	11	4,566,163	0.2	
Kidney	Total	-	35,591	-	-	1.6	0.396	386	9,175,803	4.2	
Kidney	Male	-	18,057	-	-	1.0	0.725	246	4,609,640	5.3	
Kidney	Female Total	-	17,534 35,591	-	-	0.6 0.3	1.000 1.000	140 76	4,566,163	3.1 0.8	
Larynx Larynx	Male	-	18,057	-	-	0.3	1.000	65	9,175,803 4,609,640	0.8 1.4	
Larynx	Female	-	17,534	-	-	0.0	1.000	11	4,566,163	0.2	
Leukemia	Total	4	35,591	11.2	10.3	2.8	0.610	661	9,175,803	7.2	
Leukemia	Male	3	18,057	16.6	15.9	1.6	0.441	394	4,609,640	8.5	
Leukemia	Female	1	17,534	5.7	5.1	1.2	1.000	267	4,566,163	5.8	
Liver and Bile Duct	Total	2	35,591	5.6	5.3	2.6	1.000	633	9,175,803	6.9	
Liver and Bile Duct	Male	1	18,057	5.5	5.3	1.7	0.970	422	4,609,640	9.2	
Liver and Bile Duct	Female	1	17,534	5.7	5.3	0.9	1.000	211	4,566,163	4.6	
Lung and Bronchus	Total	11	35,591	30.9	28.8	12.2	0.878	2,926	9,175,803	31.9	
Lung and Bronchus	Male	6	18,057	33.2	31.6	6.3	1.000	1,535	4,609,640	33.3	
Lung and Bronchus	Female	5	17,534	28.5	26.0	5.9	0.935	1,391	4,566,163	30.5	
Melanoma of the Skin	Total	-	35,591	-	-	1.2	0.577 0.883	301	9,175,803	3.3	
Melanoma of the Skin Melanoma of the Skin	Male Female	-	18,057 17,534	-	-	0.8 0.4	1.000	200 101	4,609,640 4,566,163	4.3 2.2	
Myeloma	Total	- 4	35,591	- 11.2	- 10.4	1.4	0.097	321	9,175,803	3.5	
Myeloma	Male	4	18,057	22.2	21.1	0.8	0.015 >>	184	4,609,640	4.0	
Myeloma	Female	-	17,534	-	-	0.6	1.000	137	4,566,163	3.0	
Non-Hodgkin Lymphoma	Total	2	35,591	5.6	5.2	2.4	1.000	566	9,175,803	6.2	
Non-Hodgkin Lymphoma	Male	2	18,057	11.1	10.7	1.3	0.714	308	4,609,640	6.7	
Non-Hodgkin Lymphoma	Female	-	17,534	-	-	1.1	0.655	258	4,566,163	5.7	
Oral Cavity and Pharynx	Total	1	35,591	2.8	2.7	1.1	1.000	274	9,175,803	3.0	
Oral Cavity and Pharynx	Male	1	18,057	5.5	5.3	0.8	1.000	191	4,609,640	4.1	
Oral Cavity and Pharynx	Female	-	17,534	-	-	0.3	1.000	83	4,566,163	1.8	
Ovary	Female	1	17,534	5.7	5.3	1.5	1.000	360	4,566,163	7.9	
Pancreas	Total	2	35,591	5.6	5.3	4.9	0.264	1,188	9,175,803	12.9	
Pancreas	Male Female	1 1	18,057 17,534	5.5 5.7	5.3 5.2	2.7 2.3	0.513 0.684	649 539	4,609,640 4,566,163	14.1 11.8	
Pancreas Prostate	Male	1	17,534	5.7	5.2 5.2	4.1	0.064	996	4,500,103	21.6	
Stomach	Total	-	35,591	5.5 -	- -	4.1	0.162	996 194	9,175,803	21.0	
Stomach	Male	-	18,057	-	_	0.5	1.000	194	4,609,640	2.1	
Stomach	Female	-	17,534	_	-	0.3	1.000	75	4,566,163	1.6	
otomaon	i cillaid	-	17,554	-	-	0.3	1.000	15	+,500,105	1.0	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Caribou County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	80.2% 13.1%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	43.1%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	20.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	19.9% 76.7% 17.7% 16.6%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Cancer Screening and Risk Factors

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.



